[1] Li JP.Heparin,heparan sulfate and heparanase in cancer:remedy for metastasis?[J].Anticancer Agents Med Chem,2008,8(1):64-76.
[2] 童旭辉,董淑英,刘浩,等.硫酸乙酰肝素蛋白聚糖对乳腺癌细胞的抑制与诱导凋亡作用[J].实用医学杂志,2008,24(12):3816-3819.
[3] 刘浩,蒋志文,童旭辉,等.硫酸乙酰肝素蛋白聚糖对C3H小鼠乳腺癌移植瘤的抑制作用及其机制[J].中国药理学通报,2008,24(6):744-748.
[4] Cohen I,Maly B,Simon I,et al.Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer[J].Clin Cancer Res,2007,13(14):4069-4077.
[5] Basche M,Gustafson DL,Holden SN,et al.A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors[J].Clin Cancer Res,2006,12(18):5471-5480.
[6] Kudchadkar R,Gonzalez R,Lewis KD.PI-88:a novel inhibitor of angiogenesis[J].Expert Opin Investig Drugs,2008,17(11):1769-1776.
[7] Marchetti D,Reiland J,Erwin B,et al.Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues[J].Int J Cancer,2003,104(2):167-174.
[8] Takashi M,Hisako M.Glycosaminoglycan-binding cytokines as tumor markers[J].Proteomics,2008,8(1):3350-3359.
[9] Yosuke N,Yusuke H,Ryoichi M.FGF-2 induces ERK phosphorylation through Grb2 and PKC during quiescent myogenic cell activation[J].Cell Structure Function,2010,35(1):63-71.
[10] Brown KJ,Hendry IA,Parish CR.Evidence that carboxyl reduced heparin fails to potentiate acidic fibroblast growth factor activity due to an inability to interact with cell surface heparin receptors[J].Exp Cell Res,1995,217(1):1322-1331.
[11] Pellegrini L,David F,Burke F,et al.Crystal structure of fibroblast growth factor receptor ecto-domain bound to ligand and heparin[J].Nature,2000,407(1):1029-1034.
[12] Noti C,Seeberger PH.Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans[J].Chem Biol,2005,12(7):7312-7316.
[13] Militsopolou M,Lamari F,Karamanos NK.Capillary electrophoresis:a tool for studying interactions of glycans/proteoglycans with growth factors[J].Pharm Biomed Anal,2003,32 (425):8232-8241.
[14] Reiland J,Sanderson RD,Waguespack M,et al.Heparanase degrades syndecan-1 and perlecan heparan sulfate:functional implications for tumor cell invasion[J].Biol Chem,2004,279(9):8047-8055.
[15] Zhao H,Liu H,Chen Y,et al.Oligomannurarate sulfate,a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor,combats tumor angiogenesis and metastasis[J].Cancer Res,2006,66(17):8779-8787.
[16] Rapraeger AC,Krufka A,Olwin BB.Requirement of heparan sulfate for FGF-2-mediated fibroblast growth and myoblast differentiation[J].Science,1991,252(5013):1705-1708.
[17] Kirn-Safran C,Farach-Carson MC,Carson DD.Multifunctionality of extracellular and cell surface heparin sulfate proteoglycans[J].Cell Mol Life Sci,2009,66(1):3421-3434.
[18] Marchetti D,Reiland J,Erwin B,et al.Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues[J].Int J Cancer,2003,104(2):167-174.
[19] Reiland J,Sanderson RD,Waguespack M,et al.Heparanase degrades syndecan-1 and perlecan heparan sulfate:functional implications for tumor cell invasion[J].Biol Chem,2004,279(9):8047-8055.
[20] Zhang ZH,Chen Y,Zhao HJ,et al.Silencing of heparanase by siRNA inhibits tumor metastasis and angiogenesis of human breast cancer in vitro and in vivo[J].Cancer Biol Ther,2007,6(4):587-595.
[21] Cohen I,Maly B,Simon I,et al.Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer[J].Clin Cancer Res,2007,13(14):4069-4077.
[22] Orosco A,Fromigue O,Bazille C,et al.Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma[J].Cancer Res,2007,67(8):3708-3715.